Answers are grounded in this paper and cite their sources.
In a prostate cancer screening program involving participants in the top decile of risk as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been identified with the use of PSA or MRI. (Funded by the European Research Council Seventh Framework Program and others; BARCODE1 ClinicalTrials.gov number, NCT03857477.).
No takes yet. Share an insight, caveat, or question.
McHugh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: